XGN (Exagen) Equivalent Admissions #: 0.00 (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XGN Exagen Inc XGN
60 GF Score
Price $4.94
GF Value $3.00
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Exagen Equivalent Admissions #?

Exagen XGN +1.65% 60 Equivalent Admissions # is 0.00 as of Mar. 2025. GuruFocus rates XGN with a GF Score™ of 60/100 and a GF Value™ of $3.00 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Equivalent Admissions # are a general measure used to indicate combined inpatient and outpatient volumes.

The historical rank and industry rank for Exagen's Equivalent Admissions # or its related term are showing as below:

XGN's Equivalent Admissions # is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median:
* Ranked among companies with meaningful Equivalent Admissions # only.

Exagen Equivalent Admissions # Historical Data

* Premium members only.

The historical data trend for Exagen's Equivalent Admissions # can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exagen Equivalent Admissions # Chart

Exagen Annual Data
Trend Dec22 Dec23 Dec24
Equivalent Admissions #
Get a 7-Day Free Trial

ExagenQuarterly Data
Trend Mar23 Jun23 Sep23 Mar25
Equivalent Admissions #
Get a 7-Day Free Trial Premium Member Only

XGN vs BNR, IMDX, IDXG: Equivalent Admissions # Comparison

For the Diagnostics & Research subindustry, Exagen's Equivalent Admissions #, along with its competitors' market caps and Equivalent Admissions # data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XGN
60GF Score
Exagen Inc XGN
Equivalent Admissions # is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions
What does a Equivalent Admissions # of 0.00 mean?
Exagen (XGN) has a Equivalent Admissions # of 0.00 as of Mar. 2025. Equivalent Admissions are a general measure used to indicate combined inpatient and outpatient volumes. View historical data on Exagen and its competitors.
Is Exagen's Equivalent Admissions # too high?
Exagen's current Equivalent Admissions # is 0.00. Overall, Exagen has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exagen's Equivalent Admissions # compare to BNR and IMDX?
Exagen's Equivalent Admissions # of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equivalent Admissions # for a Medical Diagnostics & Research company?
A good Equivalent Admissions # depends on the Medical Diagnostics & Research industry context. However, Equivalent Admissions # should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equivalent Admissions # mean?
A high Equivalent Admissions # can signal that a stock is expensive relative to its fundamentals. Equivalent Admissions are a general measure used to indicate combined inpatient and outpatient volumes. View historical data on Exagen and its competitors. Exagen's current Equivalent Admissions # is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exagen stock overvalued right now?
Based on GuruFocus' analysis, Exagen (XGN) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.00, compared to a current price of $4.94 — trading 64.7% above its estimated fair value. The current Equivalent Admissions # is 0.00. Exagen's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equivalent Admissions # calculated?
Equivalent Admissions # is calculated from a company's financial statements. For Exagen (XGN), the current Equivalent Admissions # is 0.00 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Exagen (XGN) Overvalued in 2026?

Based on GuruFocus' analysis, Exagen stock appears to be overvalued. The current stock price of $4.94 is trading 64.7% above its estimated GF Value™ of $3.00. GuruFocus considers Exagen to be Significantly Overvalued.

Key valuation signals for XGN:

  • Equivalent Admissions #: 0.00
  • GF Value™: $3.00 vs. price of $4.94 (64.7% above fair value)
  • GF Score™: 60/100 with 3 warning signs

No single metric tells the full story. See the XGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Exagen Business Description

Other Exchanges E08A:Germany
Address 1261 Liberty Way, Vista, CA, USA, 92081
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
60GF Score

Get the complete analysis for XGN

Equivalent Admissions # is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.94
Price
$3.00
GF Value